The Research Report on “Allergy Diagnostics Market by Products (Assay Kits, Immunoassay & Elisa Analyzers, Luminometers, Services), Allergens (Food, Inhaled, Drug), Tests (In Vivo, In Vitro), End Users (Hospital, Diagnostic Laboratory) – Global Forecast” published by MarketsandMarkets™, the market witnessed healthy growth during the last decade and is expected to grow at a CAGR of 10.5%, and projected to reach USD 5.74 Billion.
The allergy diagnosis is an important introductory step for effective allergy treatment. Current allergy tests are more convenient and accurate compared to the tests that were available before. With the help of a detailed medical history, allergy tests can identify specific triggers for an individual’s allergic reactions. This process is also required in drug development and the production process of allergy treatments.
The major factors driving the growth of this market are the high incidence and large economic burden of allergic diseases, rising environmental pollution, increasing healthcare expenditure, and growing access to medical insurance in the US. On the other hand, lack of awareness of allergic diseases in some countries is restraining the growth of this market.
Request Research Sample Pages:
Opportunity: Growing adoption of automation for quicker turnaround times;
Turnaround time (TAT) is an important factor in laboratory services and is often used as a key indicator of laboratory performance. Fully automated immunoassay systems are popular as they improve the TAT of laboratories and reduce labor costs. Semi-automated instruments are also preferred as they are less expensive; however, these systems increase the TAT. To meet the requirement of increased on-board testing capacity, advanced allergy diagnostic tests have been introduced in the market. Also, the market is witnessing greater adoption of automation for quicker TAT.
Automation in laboratories helps increase the efficiency of laboratory workflows, thus maintaining high throughputs. The main objective of automation in laboratories is to minimize nonvalue-adding steps, such as tube sorting, centrifugation, loading of analyzers, and preparing and sorting of materials required for testing. Some large laboratory chains are now shifting toward complete or total laboratory automation (TLA). However, these laboratories require major financial commitment.
The inhaled allergens segment is expected to grow at the highest CAGR during the forecast period
Based on the allergen, the allergy diagnostics market is segmented into inhaled allergens, food allergens, drug allergens, and other allergens. The inhaled allergens segment is expected to witness the highest growth during the forecast period owing to the increasing environmental pollution levels across the globe.
Download PDF Brochure:
Geographical View in-detailed:
The allergy diagnostics market is segmented into four major regions, namely, North America, Europe, Asia, and the Rest of the World. North America accounted for the largest share of this market owing to the high healthcare expenditure and the strong presence of key market players in the region. These factors, coupled with the rising prevalence of different types of allergies, have resulted in the wide availability and adoption of various allergy diagnostic products and services in the US and Canada.
Global Key Leaders:
The key players operating in the allergy diagnostics market include Thermo Fisher Scientific Inc. (US), Siemens AG (Germany), Danaher Corporation (US), Omega Diagnostics Group PLC (UK), Hitachi Chemical Co., Ltd. (Japan), bioMérieux SA (France), Stallergenes Greer (UK), HOB Biotech Group Suzhou Co., Ltd. (China), HYCOR Biomedical (US), Lincoln Diagnostics, Inc. (US), EUROIMMUN AG (Germany), INDOOR Biotechnologies, Inc. (US), DR. FOOKE – Achterrath Laboratorien GmbH (Germany), R-Biopharm AG (Germany), GA Generic Assays GmbH (Germany), Tecan Trading AG (Switzerland), DST Diagnostische Systeme & Technologien GmbH (Germany), ROXALL Medical GmbH (Germany), ALK-Abelló A/S (Denmark), Astra Biotech GmbH (Germany), HAL Allergy Group (Netherlands), Theradiag (France), and Demeditec Diagnostics GmbH (Germany)